Medexus Pharmaceuticals (TSE:MDP) Shares Up 2.4% – Still a Buy?

Medexus Pharmaceuticals Inc. (TSE:MDP) shot up 2.4% on Monday . The stock traded as high as C$3.19 and last traded at C$3.00. 55,522 shares changed hands during trading, a decline of 34% from the average session volume of 83,952 shares. The stock had previously closed at C$2.93.

Medexus Pharmaceuticals Price Performance

The company has a market capitalization of C$67.16 million, a PE ratio of 14.35 and a beta of 1.96. The company has a 50-day moving average of C$2.69 and a two-hundred day moving average of C$2.98.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.